Barriers to accrual and enrollment in brain tumor trials

Author:

Lee Eudocia Q12,Chukwueke Ugonma N12,Hervey-Jumper Shawn L3,de Groot John F4,Leone Jose Pablo12,Armstrong Terri S5,Chang Susan M3,Arons David6,Oliver Kathy7,Verble Kay8,Musella Al9,Willmarth Nicole10,Alexander Brian M11,Bates Amanda6,Doherty Lisa6,Galanis Evanthia12,Gaffey Sarah1,Halkin Thomas1,Friday Bret E13,Fouladi Maryam14,Lin Nancy U1,Macdonald David15,Mehta Minesh P16,Penas-Prado Marta5,Vogelbaum Michael A17,Sahebjam Solmaz17,Sandak David18,van den Bent Martin19,Weller Michael20ORCID,Reardon David A1,Wen Patrick Y1

Affiliation:

1. Dana-Farber Cancer Institute, Boston, Massachusetts, USA

2. Harvard Medical School, Boston, Massachusetts, USA

3. University of California San Francisco, San Francisco, California, USA

4. MD Anderson Cancer Center, Houston, Texas, USA

5. Neuro-Oncology Branch, National Cancer Institute, National Institutes of Health, Bethesda, Maryland, USA

6. National Brain Tumor Society, Newton, Massachusetts, USA

7. International Brain Tumour Alliance, Tadworth, Surrey, UK

8. The Sontag Foundation and Brain Tumor Network, Ponte Vedre Beach, Florida, USA

9. The Musella Foundation for Brain Tumor Research and Information, Hewlett, New York, USA

10. American Brain Tumor Association, Chicago, Illinois, USA

11. Foundation Medicine, Cambridge, Massachusetts, USA

12. Mayo Clinic, Rochester, Minnesota, USA

13. Essentia Health, Duluth, Minnesota, USA

14. Cincinnati Children’s Hospital Medical Center, Cincinnati, Ohio, USA

15. University of Western Ontario, London, Ontario, Canada

16. Miami Cancer Institute, Miami, Florida, USA

17. Moffitt Cancer Center, Tampa, Florida, USA

18. Accelerate Brain Cancer Cure (ABC2), Washington, DC, USA

19. Erasmus University Hospital, Rotterdam, Netherlands

20. University Hospital and University of Zurich, Zurich, Switzerland

Abstract

Abstract Many factors contribute to the poor survival of malignant brain tumor patients, some of which are not easily remedied. However, one contributor to the lack of progress that may be modifiable is poor clinical trial accrual. Surveys of brain tumor patients and neuro-oncology providers suggest that clinicians do a poor job of discussing clinical trials with patients and referring patients for clinical trials. Yet, data from the Cancer Action Network of the American Cancer Society suggest that most eligible oncology patients asked to enroll on a clinical trial will agree to do so. To this end, the Society for Neuro-Oncology (SNO) in collaboration with the Response Assessment in Neuro-Oncology (RANO) Working Group, patient advocacy groups, clinical trial cooperative groups, including the Adult Brain Tumor Consortium (ABTC), and other partners are working together with the intent to double clinical trial accrual over the next 5 years. Here we describe the factors contributing to poor clinical trial accrual in neuro-oncology and offer possible solutions.

Funder

Adult Brain Tumor Consortium

National Institutes of Health

National Cancer Institute

Publisher

Oxford University Press (OUP)

Subject

Cancer Research,Neurology (clinical),Oncology

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3